Tesamorelin

Growth Hormone SecretagogueResearch Use Only

Also known as: TH9507, Egrifta

An FDA-approved GH-releasing peptide (for belly fat in HIV patients), studied for visceral fat loss.

Dosing quick reference

research reference

Starting dose

1 mg once daily (week 1)

Frequency

Once daily (evening)

Typical range

1–2 mg per day

Cycle

12–26 weeks

Titration (step-up)

Wk 1: 1 mg → Wk 2+: 2 mg

Half-life

~25–40 minutes

Route

Subcutaneous (research)

Common use

Studied for effects on visceral fat and the growth-hormone axis in research contexts

Common vial sizes

5 mg · 10 mg · 20 mg

Storage

Lyophilized powder stored refrigerated or frozen away from light; reconstituted solution refrigerated (2–8 °C) and used within a few weeks

Stacking notes

Sometimes discussed alongside a GHRP for combined growth-hormone axis research; often studied on its own

Reported side effects

Injection-site reactionJoint aches reported anecdotallyFluid retention reported anecdotallyTransient glucose changes cited in studies

Regulatory note: Approved as a prescription drug (brand Egrifta) for a specific clinical indication in some jurisdictions; research-market products are sold for research purposes only

Calculate a dose →Tesamorelin on The Peptide Guide →Deeper research reference: literature dose ranges, storage and handling, and where to source in Canada.

Dose figures are ranges commonly referenced in research literature, not recommendations or medical advice. Research-only labeling does not establish that a substance is safe, approved or appropriate for personal use. Consult a qualified healthcare professional about health decisions.